Tyrosine and tryptophan in urine as biomarkers for prostate cancer: A validation study
Journal of Pharmaceutical and Biomedical Analysis · 2024
DOI: 10.1016/j.jpba.2024.116398 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Pharmaceutical and Biomedical Analysis, 2024. Verfasst von Hashmatullah Nasimi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Science and Environment, Roskilde University, Universitetsvej 1, Roskilde, Denmark; Department of Biochemistry and Immunology, Lillebae…. Hauptthemen laut MEDLINE: Tryptophan, Tyrosine, Prostatic Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sygehus Lillebælt.
Abstract (Originalsprache)
Prostate cancer (PCa) is a common male malignancy and early diagnosis is crucial for successful treatment. The current study aims to validate results from a pilot study that demonstrated an inverse association between urine tyrosine and tryptophan levels and the severity of PCa. This study comprised a cohort of 97 patients with benign prostatic hyperplasia, 93 patients diagnosed with localized PCa, 75 patients diagnosed with locally advanced PCa, and 68 patients diagnosed with metastatic PCa. The tyrosine and tryptophan levels in the samples were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and electrochemical sensors in accordance with the pilot to maintain uniformity for accurately evaluating the data. One-way ANOVA with post Tukey test as well as the Wilcoxon Rank Sum Test were performed. Analyzing 333 patients across PCa stages with consistent methods, we observed no significant differences in tyrosine and tryptophan levels between PCa patients and controls, finally rejecting the use of tyrosine and tryptophan as PCa biomarkers. We did, however, verify the strong correlation between the urinary concentrations of tyrosine and tryptophan found in the pilot study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Science and Environment, Roskilde University, Universitetsvej 1, Roskilde, Denmark; Department of Biochemistry and Immunology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
- Department of Biochemistry and Immunology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
- Department of Oncology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
- Department of Biochemistry and Immunology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
- Department of Science and Environment, Roskilde University, Universitetsvej 1, Roskilde, Denmark.
- Department of Urology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Förderung
- Sygehus Lillebælt
Zitieren
APA
Nasimi, H., Madsen, J. S., Zedan, A. H., Schmedes, A. V., Malmendal, A., Osther, P. J. S., & Alatraktchi, F. A. (2024). Tyrosine and tryptophan in urine as biomarkers for prostate cancer: A validation study. Journal of Pharmaceutical and Biomedical Analysis. https://doi.org/10.1016/j.jpba.2024.116398
Vancouver
Nasimi H, Madsen JS, Zedan AH, Schmedes AV, Malmendal A, Osther PJS, et al. Tyrosine and tryptophan in urine as biomarkers for prostate cancer: A validation study. Journal of Pharmaceutical and Biomedical Analysis. 2024. doi:10.1016/j.jpba.2024.116398
BibTeX
@article{Nasimi2024,
author = {Nasimi, Hashmatullah and Madsen, Jonna Skov and Zedan, Ahmed H and Schmedes, Anne Vibeke and Malmendal, Anders and Osther, Palle Jörn Sloth and Alatraktchi, Fatima AlZahra'a},
title = {Tyrosine and tryptophan in urine as biomarkers for prostate cancer: A validation study},
journal = {Journal of Pharmaceutical and Biomedical Analysis},
year = {2024},
doi = {10.1016/j.jpba.2024.116398}
}
EUVIMED